Lacunar infarction is an ischemic stroke occurred by small perforating artery occlusion . Twenty percent of ischemic stroke is lacunar infarction. However, outcome of lacunar infarction is excellent, about 20-40% patients are suffered neurological worsening. Progressive lacunar infarction is associated poor functional outcome and neurological deficit. Currently, no treatment for progressive lacunar infarction is recommended on the guideline. Several small study reported that phenylephrine and magnesium may be helpful for progressive lacunar infarction. Carbogen is a mixture of 5% CO2 with 95% O2. Carbogen is safe and it is used for the treatment of sudden sensory neural hearing loss or ocular ischemia. CO2 dilate cerebral arteriole and concentration of CO2 is correlated with cerebral blood flow. Lacunar infarction is small and perfused with marginal flow by neighboring perforating arteriole. Increased cerebral blood flow following dilation of cerebral arteriole by CO2 might halt and revert progressive lacunar infarction. Induced hypertension is alternative treatment of progressive lacunar infarction. Increasing blood pressure also induce cerebral blood flow. Phenylephrine is an α1 agonist, phenylephrine act on peripheral artery and little effect on cerebral artery or heart. Several studies reported that the effectiveness of phenylephrine on progressing stroke. Therefore, this study will compare the effectiveness of carbogen versus phenylephrine in lacunar infarction patients who suffered neurological worsening.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
3
Patients will inhale carbogen gas for 10 minutes and rest for 50 minutes.
Start phenylephrine with 0.5 mg/hr and titrate upto 3.5 mg/hr or systolic blod pressure 200 mmHg.
Yonsei University Health System, Severance Hospital
Seoul, South Korea
percent improvement of NIHSS score in each group
(baseline NIHSS score-post-treatment NIHSS score)/baseline NIHSS score×100
Time frame: 48 hours
difference of NIHSS score in each group
baseline NIHSS score-post-treatment NIHSS score
Time frame: 48 hours
percent improvement of MRC score in each group
(baseline MRC score-post-treatment MRC score)/baseline MRC score×100
Time frame: within 48 hours
difference of MRC score in each group
baseline MRC score-post-treatment MRC score
Time frame: within 48 hours
Safety outcome: Side effect
Side effect (cerebral hemorrhage, myocardial infarction, Losing consciousness, difficulty breathing, dizziness, fatigue, headache, anxiety, etc)
Time frame: within 7 days
Safety outcome: discontinuing patients
Number of discontinuing patients due to side effects
Time frame: within 7 days
Comparison between groups by percent improvement of NIHSS score
(baseline NIHSS score-post-treatment NIHSS score)/baseline NIHSS score×100
Time frame: 48 hours
Comparison between groups by difference of NIHSS score
baseline NIHSS score-post-treatment NIHSS score
Time frame: 48 hours
Comparison between groups by percent improvement in MRC score
(baseline MRC score-post-treatment MRC score)/baseline MRC score×100
Time frame: within 48 hours
Comparison between groups by difference of MRC score
baseline MRC score-post-treatment MRC score
Time frame: within 48 hours
Functional independence
modified Rankin score 0 to 2
Time frame: upon discharge, 3 months after onset
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.